| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $...
Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareh...
Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings...
GOOG: 5% | Alphabet Inc shares are trading higher after Berkshire Hathaway disclosed a new stake in the company. ZYME: 61% | Zy...
Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab a...